HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a single arm, phase 4, prospective, open-label, United States single-center study to
assess the hemostatic efficacy and safety of Hemlibra (emicizumab) for hemostatic control of
hemophilia A patients (baseline FVIII level <40%) with and without inhibitors with hemophilic
pseudotumors; secondary outcomes will assess changes in quality of life and activity level in
treated patients.